Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
TARGET-D 201
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- NCT07644559 ↗
- Recruiting
- Verastem, Inc.
- Focused
We haven't built an HCP commentary report on TARGET-D 201 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TARGET-D 201 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC); G12D Mutated KRAS
- Interventions
- VS-7375; cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
- Arms
- VS-7375 Monotherapy · Experimental
- VS-7375 + cetuximab 2L PDAC · Experimental
- VS-7375 + cetuximab 1L PDAC · Experimental
- Enrollment
- 185 (estimated)
- Primary outcomes
- Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1
- To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab, administered on a daily oral schedule in participants with KRAS G12D-mutated PDAC.
- Sponsor
- Verastem, Inc.
- Start
- Jun 16, 2026
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT07644559 · updated Oct 23, 2026